Advertisement

Myxoid spindle cell sarcoma with ETV6‐NTRK3 fusion

      Abstract

      Myxoid spindle cell sarcoma is a rare sarcoma with a demanding histopathologic diagnosis due to the absence of pathognomic immunohistochemistry markers. Genetics include complex karyotypic alterations without characteristic molecular abnormalities for this entity. NTRK alterations are rare findings with great clinical importance since they can be therapeutically targeted with two NTRK inhibitors. Herein we present a case of an adult unclassified myxoid spindle cell sarcoma with ETV6/NTRK3 fusion gene, which is a molecular finding characteristic for infantile fibrosarcoma.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Roland C.L.
        • Wang W.L.
        • Lazar A.J.
        • Torres K.E.
        Myxofibrosarcoma.
        Surg Oncol Clin N Am. 2016; 25: 775-788
        • Sambri A.
        • De Paolis M.
        • Spinnato P.
        • Donati D.M.
        • Bianchi G.
        The biology of myxofibrosarcoma: state of the art and future perspectives.
        Oncol Res Treat. 2020; 43: 314-322
        • Widemann B.C.
        • Italiano A.
        Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: state of the Art and Perspectives.
        J Clin Oncol. 2018; 36: 160-167
        • Solomon J.P.
        • Benayed R.
        • Hechtman J.F.
        • Ladanyi M.
        Identifying patients with NTRK fusion cancer.
        Ann Oncol. 2019; 30 (Supplviii16-viii22)
        • Brcic I.
        • Godschachner T.M.
        • Bergovec M.
        • Igrec J.
        • Till H.
        • Lackner H.
        • Scheipl S.
        • Kashofer K.
        • Brodowicz T.
        • Leithner A.
        • et al.
        Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions.
        Mod Pathol. 2021; 34: 396-407
        • Forsythe A.
        • Zhang W.
        • Phillip Strauss U.
        • Fellous M.
        • Korei M.
        • Keating K.
        A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors.
        Ther Adv Med Oncol. 2020; 121758835920975613
        • Demetri G.D.
        • Antonescu C.R.
        • Bjerkehagen B.
        • Bovee J.
        • Boye K.
        • Chacon M.
        • Dei Tos A.P.
        • Desai J.
        • Fletcher J.A.
        • Gelderblom H.
        • et al.
        Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
        Ann Oncol. 2020; 31: 1506-1517
        • Solomon J.P.
        • Hechtman J.F.
        Detection of NTRK Fusions: merits and Limitations of Current Diagnostic Platforms.
        Cancer Res. 2019; 79: 3163-3168
        • Knezevich S.R.
        • McFadden D.E.
        • Tao W.
        • Lim J.F.
        • Sorensen P.H.
        A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.
        Nat Genet. 1998; 18: 184-187
        • Orbach D.
        • Sparber-Sauer M.
        • Laetsch T.W.
        • Minard-Colin V.
        • Bielack S.S.
        • Casanova M.
        • Corradini N.
        • Koscielniak E.
        • Scheer M.
        • Hettmer S.
        • et al.
        Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: international consensus and remaining controversies.
        Eur J Cancer. 2020; 137: 183-192
        • Hong D.S.
        • DuBois S.G.
        • Kummar S.
        • Farago A.F.
        • Albert C.M.
        • Rohrberg K.S.
        • van Tilburg C.M.
        • Nagasubramanian R.
        • Berlin J.D.
        • Federman N.
        • et al.
        Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
        Lancet Oncol. 2020; 21: 531-540
        • Doebele R.C.
        • Drilon A.
        • Paz-Ares L.
        • Siena S.
        • Shaw A.T.
        • Farago A.F.
        • Blakely C.M.
        • Seto T.
        • Cho B.C.
        • Tosi D.
        • et al.
        Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
        Lancet Oncol. 2020; 21: 271-282
        • Argani P.
        • Fritsch M.
        • Kadkol S.S.
        • Schuster A.
        • Beckwith J.B.
        • Perlman E.J.
        Detection of the ETV6-NTRK3 chimeric RNA of infantile fibrosarcoma/cellular congenital mesoblastic nephroma in paraffin-embedded tissue: application to challenging pediatric renal stromal tumors.
        Mod Pathol. 2000; 13: 29-36
        • Yamazaki F.
        • Nakatani F.
        • Asano N.
        • Wakai S.
        • Sekimizu M.
        • Mitani S.
        • Kubo T.
        • Kawai A.
        • Ichikawa H.
        • Yoshida A.
        Novel NTRK3 Fusions in Fibrosarcomas of Adults.
        Am J Surg Pathol. 2019; 43: 523-530
        • Wong D.D.
        • Vargas A.C.
        • Bonar F.
        • Maclean F.
        • Kattampallil J.
        • Stewart C.
        • Sulaiman B.
        • Santos L.
        • Gill A.J.
        NTRK-rearranged mesenchymal tumours: diagnostic challenges, morphological patterns and proposed testing algorithm.
        Pathology. 2020; 52: 401-409
        • Siozopoulou V.
        • Smits E.
        • De Winne K.
        • Marcq E.
        • Pauwels P.
        NTRK fusions in sarcomas: diagnostic challenges and clinical aspects.
        Diagnostics (Basel). 2021; 11
        • Lam S.W.
        • Cleton-Jansen A.M.
        • Cleven A.H.G.
        • Ruano D.
        • van Wezel T.
        • Szuhai K.
        • Bovee J.
        Molecular analysis of gene fusions in bone and soft tissue tumors by anchored multiplex PCR-based targeted next-generation sequencing.
        J Mol Diagn. 2018; 20: 653-663
        • Lohberger B.
        • Stuendl N.
        • Leithner A.
        • Rinner B.
        • Sauer S.
        • Kashofer K.
        • Liegl-Atzwanger B.
        Establishment of a novel cellular model for myxofibrosarcoma heterogeneity.
        Sci Rep. 2017; 7: 44700